104 results about "Glucose absorption" patented technology

The present invention encompasses a model-based method for determining insulin sensitivity and glucose absorption from oral glucose tolerance tests or mixed meals. The present invention has several advantages over current methods. The technique requires about four to six blood samples taken over about two to three hours following glucose ingestion and is therefore applicable to large-scale clinical trials. The analysis involves a reduced version of the classical minimal model, a method for describing glucose absorption using only two parameters, and an integral approach enabling the parameters to be obtained using simple algebra. The present method robustly identifies differences in insulin sensitivity in different patient types as well as improvements in insulin sensitivity arising from pharmaceutic therapy. In addition, insulin sensitivity measurements obtained with the present method are highly correlated with results from hyperinsulinemic clamps (r2>0.8). This method is therefore a practical and robust method for determining insulin sensitivity under physiologic conditions.

The present invention includes an endoluminal sleeve having a stomach sleeve portion, an antral sleeve portion, and an intestine sleeve portion. The endoluminal sleeve includes a flexible core layer which is formed from a self-expanding material. The flexible core layer in the stomach sleeve portion can self expand to grip the stomach. The antral sleeve is located in the pyloric antrum and is connected to the stomach sleeve portion and the intestine sleeve portion. The intestine sleeve portion is connected to the antral sleeve through a junction. The junction contains non-self-expanding material allowing the pyloric sphincter to properly function. The intestine sleeve portion is located in the small intestines. The intestine sleeve portion can have fenestrations, roots, a nutrient delivery layer, a nutrient delivery cover, an outer shell with a plurality of holes, and / or a semi-porous skin for nutrient delivery to the small intestines.

Provided is a novel C-phenyl glycitol compound that may serve as a prophylactic or therapeutic agent for diabetes by inhibiting both SGLT1 activity and SGLT2 activity, thereby exhibiting a glucose absorption suppression action and a urine glucose excretion action. A C-phenyl glycitol compound represented by a formula (I) below (as figure 1) or a pharmaceutically acceptable salt thereof or a hydrate thereof wherein R1 and R2 are the same or different and represent a hydrogen atom, a hydroxyl group, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, R3 is a hydrogen atom, a C1-6 alkyl group, a C1-6 alkoxy group or a halogen atom, Y is a C1-6 alkylene group, -O-(CH2)n- (n is an integer of 1 to 4) or a C2-6 alkenylene group, provided that when Z is NHC(= NH)NH2 or -NHCON(R)RC, n is not 1, Z is -CONHRA, -NHC(=NH)NH2 or -NHCON(R)RC, (as figure 2).

The invention provides fucoidan sulfate and an application of low-molecular-weight fucoidan sulfate in preparation of metabolic syndrome resistant medicines and health products. By adopting fucoidan sulfate, insulin signaling pathways can be relatively well improved, gluconeogenesis can be inhibited, the glycogen synthesis quantity can be increased, the glucose absorption of the skeletal muscles can be promoted, and insulin resistance can be effectively improved. Fucoidan sulfate can be taken as a natural product or medicine to be used for preventing and treating insulin resistance and metabolic syndromes; and fucoidan sulfate is sourced from marine algae, has the advantages of rich resources, easiness in industrialization and high safety, and has wide market and application prospects on the aspects of preventing and treating the metabolic syndromes. Fucoidan sulfate and the application provided by the invention can be used for providing reference significance and enlightenments for high-value applications of the marine algae.

The invention discloses collagen-containing compound nutritious powder, which consists of collagens, oil powder, tartary buckwheat flour, kudzuvine root, pseudo-ginseng powder, cocoa powder and protein sugar. The oil powder of the collagen-containing compound nutritious powder contains fatty acids and vitamins required by human bodies, can achieve the effect of recovering physical abilities of sub-healthy people as soon as possible, and is suitable for long-term consumption to supplement the deficient vitamins and fatty acid Omega 3, effectively prevent cardiovascular diseases, achieve important effects on the prevention and cerebral apoplexy and intracerebral hemorrhage and simultaneously achieve a good effect on the expelling of toxins. The collagens of the collagen-containing compound nutritious powder have the effect of supplementing proteins and amino acids. The tartary buckwheat of the collagen-containing compound nutritious powder has the effects of improving microcirculation, enhancing islet beta cellular nutrition and metabolism, retarding the decomposition of polysaccharides and the absorption of glucose and keeping good defaecation. The pseudo-ginseng powder of the collagen-containing compound nutritious powder has the effects of lowering blood pressure, regulating a blood sugar level and reducing blood fat. The kudzuvine root of the collagen-containing compound nutritious powder has the effects of heat clearing, internal heat decreasing, disintoxication, blood pressure lowering and the like.

The present invention encompasses a model-based method for determining insulin sensitivity and glucose absorption from oral glucose tolerance tests or mixed meals. The present invention has several advantages over current methods. The technique requires about four to six blood samples taken over about two to three hours following glucose ingestion and is therefore applicable to large-scale clinical trials. The analysis involves a reduced version of the classical minimal model, a method for describing glucose absorption using only two parameters, and an integral approach enabling the parametersto be obtained using simple algebra. The present method robustly identifies differences in insulin sensitivity in different patient types as well as improvements in insulin sensitivity arising from pharmaceutic therapy. In addition, insulin sensitivity measurements obtained with the present method are highly correlated with results from hyperinsulinemic clamps (r<2>>0.8). This method is thereforea practical and robust method for determining insulin sensitivity under physiologic conditions.

The invention relates to vigour-consolidating porridge with low glycemic index after dinner and further relates to a factory preparation method of the health-care porridge. The vigour-consolidating porridge with low glycemic index comprises the following solid ingredients and contents: 23.1-38.5 percent of black rice, 27.5-42.9 percent of barley, 6.8 percent of chickpea, 11.9 percent of mung bean, 6.8 percent of soybean, 3.4 percent of red lentil and 5.1 percent of konjac; and liquid ingredient is an oat fiber aqueous solution, in which the proportion of oat fiber to water is 1: 26. According to the vigour-consolidating porridge with low glycemic index, disclosed by the invention, adopts organic raw materials and is prepared by completely using a physical processing method without adding any preservatives, so that all natural nutrients in the raw materials are preserved; in addition, a functional food base material, that is, oat fiber is added in the processing process; the oat fiber can be used for effectively limiting absorption of fat in digestive tracts, promoting excretion of lipid compounds, increasing satiety, reducing food intake and promoting slowing of glucose absorption, so that the blood glucose level after dinner is lowered, the blood lipid is lowered and the obesity is prevented.

Optical methods and devices are provided for the reduction of the lipid content of adipocytes without significant heat or intolerable adverse effect on the cells and their surrounding tissues. The optical method and device can be used to irradiate adipose tissue through the skin with non-thermal and non-destructive effects by application of near infrared (NIR) irradiation at selected wave bands in selected ranges to affect modulation of innate enzymatic processes involved in lipolysis, lipogenesis, leptin secretion, adiponectin secretion, and / or glucose absorption.

The invention relates to benzimidazolyl thiazolidinone compounds and a synthesis method thereof. The compounds have a structure shown by a general formula (I), wherein R1 and R2 may be methyl, ethyl, benzyl, alkyl or hydrogen; and n is an integer between 1 and 5. The benzimidazolyl thiazolidinone compounds provided by the invention are high-affinity ligands having specificity against peroxisome proliferator-activated receptor (PPAR-gamma), by improving glucose absorption by cells and lowering output of glycogen, the sensitivity of cells to insulin is increased and the antagonism of tissues against glucose; and the compounds, compared with the conventional thiazolidinones PPAR-gamma activating agent, has high lipid solubility, is easier to pass through blood brain barrier, improves the sensitivity of insulin in brain, and can be used for treating neurological diseases caused by diabetes and neuroprotection.

Provided are a method for detecting a free rare tumor cell in a human biological fluid sample and assay kit. Specifically, the method of the invention determines the existence of an active tumor cell in a biological fluid sample of a cancer patient by detecting and confirming the existence of glucose absorption capability of a karyocyte and expression of a leukocyte marker (CD45).

The invention provides berberrubine 12-site derivatives with a structure shown in a formula (I) or physiologically-acceptable salt thereof, applications of the derivatives and a medicament combination comprising the derivatives. Invitro cell experiments show that the berberrubine 12-site derivatives play roles in promoting adipose cells and muscle cells to absorb glucose and improving the sugar tolerance and insulin resistance; and the compound can be used for treating diabetes, obesity, fatty liver and complications thereof caused by insulin resistance.

The invention discloses a sugar-controlled sweetheart cake, in particular to a sweetheart cake for stopping saccharose and glucose from being absorbed. The sugar-controlled sweetheart cake is prepared from the following components in percentage by mass: oil skin: 10 to 90 percent of high-gluten flour, 1 to 60 percent of low-gluten flour, 5 to 30 percent of edible oil, 10 to 50 percent of water or maltitol (liquid), 10 to 50 percent of saccharose, 1 to 30 percent of tagatose and 1 to 30 percent of L-arabinose; flaky pastry: 1 to 100 percent of low-gluten flour, 20 to 30 percent of edible oil and 1 to 10 percent of shelled melon-seed; filling: 1 to 100 percent of glutinous rice flour, 10 to 50 percent of saccharose, 1 to 20 percent of salad oil, 1 to 30 percent of tagatose, 1 to 30 percent of L-arabinose and a proper amount of water or maltitol (liquid). A production method comprises the following steps: firstly, preparing the filling; secondly, preparing the oil skin; thirdly, preparing the flaky pastry; fourthly, preparing a wrapper; fifthly, wrapping the filling; sixthly, baking. According to the sugar-controlled sweetheart cake disclosed by the invention, the L-arabinose and the tagatose are added in raw materials, thus stopping the absorption of a human body to the saccharose and the glucose, inhibiting the increasing of postprandial blood sugar and reducing the intake of fat.

The invention provides a hypoglycemic peptide with the amino acid sequence ADWGGPLPH shown as SEQ ID NO:1 and further provides a modified peptide of the hypoglycemic peptide. Chemical groups, amino acids, polypeptides, proteins or PEG is connected to an N terminal, a C terminal or intermediate residues of the hypoglycemic peptide. Through the hypoglycemic peptide, glucose absorption of smooth muscle cells under the high-glucose condition can be promoted, the glucose tolerance of diabetic mice can be improved, the blood glucose utilization ability of the mice can be enhanced, serum total cholesterol and total triglycerides are significantly reduced, the SOD level is significantly improved, the MDA level is lowered, the oxidative injury of the livers of the diabetic mice is repaired, inflammatory factors in plasma of the diabetic mice are inhibited, and the hypoglycemic peptide can resist metabolic syndromes and can be used for preparing drugs or health care products for treating and / orpreventing diabetes or hyperlipidemia.

The invention discloses a coarse food grain sugar-reducing flour and a preparation method thereof, and is characterized in that the flour is prepared from the following raw materials in parts by weight: 500-530 parts of wheat, 10-12 parts of wheat germs, 20-22 parts of potatoes, 2-3 parts of lard oil, 10-11 parts of corn, 8-9 parts of sorghum rice, 13-14 parts of purple rice, 10-11 parts of red yeast rice, 3-4 parts of hazelnut kernel, 6-7 parts of Brazil nuts, 4-5 parts of soybean,16-18 parts of a sweet-sour plum juice, 20-22 parts of a coconut juice, 3-4 parts of radix astragali, 4-5 parts of caulis dendrobii flowers, 2-3 parts of corn stigma, 3-4 parts of American ginseng, 2-3 parts of apple flowers, 1-2 parts of lindernia oblonega, 2-3 parts of leea compactiflora kurz, 0.5-0.6 parts of lactic acid bacteria, and 10-11 parts of a nutrition additive. The flour is fine and smooth in mouthfeel, unique in flavor, and reasonable and scientific in formula; various added coarse food grains contain rich insoluble cellulose, can increase the residence time of food in a stomach, and delays the absorption rate of glucose after meals; and with collocation of caulis dendrobii flowers, corn stigma and various Chinese herbal medicines, the flour can reach the blood sugar reducing efficacy.

A medicament comprising a pharmaceutically acceptable anion exchange resin as an active ingredient is provided which exhibits an insulin resistance-improving action regardless of volume of meal or glucose absorption from the gastrointestinal tract.

The present invention provides 4-isopropylphenyl glucitol compounds which have no tendency to accumulate in the body and which inhibit SGLT1 activity to suppress postprandial hyperglycemia (or impaired glucose tolerance) through suppression of glucose absorption in the small intestine, whereby the compounds, for example, can suppress the onset of diabetes and metabolic syndrome or can treat these diseases.A 4-isopropylphenyl glucitol compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof:wherein R1 represents a hydrogen atom, etc., R2 represents a methyl group, etc., R3 represents a C1-4 alkyl group substituted with an amino group(s), etc., and R4 represents a hydrogen atom, etc.

The invention discloses protein associated with hexose transport and a coding gene and an application thereof. The protein provided by the invention is the following 1) or 2): 1) protein composed of an amino acid sequence shown in sequence 2 in the sequence table; 2) protein which is obtained by substitution, deletion or addition of one or more amino acid residues of the amino acid residue sequence in the sequence 2 in the sequence table, is associated with hexose transport, and is derived from 1). Experiments prove that the CsHT1 protein provided by the invention can recover the glucose absorption function of yeast mutant with hexose transport defects, which proves that the cucumber hexose carrier protein CsHT1 has the glucose absorption function. These results show that the protein CsHT1 associated with hexose transport and the coding gene thereof can be used for regulating glycometabolism in cucumbers, and improving cucumber quality, and are widely applicable to research of glycometabolism in plants.

Two coherent narrow bandwidth infrared beams, the Signal and the Reference, are incident at an angle and at high frequency sequentially and alternately at the same spot of a whole blood / body tissues sample. The Signal beam has a center wavelength which falls within an absorption line of glucose in whole blood (e.g. 1.409μ). The Reference beam has a center wavelength which does not coincide with any known absorption lines of glucose in whole blood (e.g. 1,278μ). Radiation emitted from the spot at which the beams penetrate into the sample and subsequently emanate from it after multiple scattering and spurious absorption effects is collected by a lens onto an infrared detector. The ratio of the voltage detected from the emerging Signal beam over that of the Reference beam is processed to yield the value of glucose concentration in the whole blood / body tissue sample.

A 1-phenyl 1-thio-D-glucitol compound represented by formula (I) or the like:or a pharmaceutically acceptable salt thereof or a hydrate thereof, or a pharmaceutical preparation comprising the same as an active ingredient is useful as a novel type of prophylactic or therapeutic agent for diabetes, diabetes-related diseases or diabetic complications, which inhibits both SGLT1 and SGLT2 activities to achieve not only suppression of glucose absorption from the digestive tract but also excretion of urinary sugars.

The invention discloses a sugar-controlled fried dough twist for restraining saccharose and glucose absorption. The sugar-controlled fried dough twist is prepared from, by mass, 5-80% of flour, 0.2-5% of yeast, 0.1-30% of L-arabinose, 0.1-30% of tagatose, 5-50% of saccharose, 3-16% of eggs, 3-14% of linseed oil, 0.2-5% of baking powder, 0.2-6% of edible alkali, 0.1-2% of edible salt and 9-13% of warm water. The manufacturing method of the sugar-controlled fried dough twist comprises the steps of 1, manufacturing a leavened dough; manufacturing a dough; 3, performing segmentation; 4, manufacturing a crude twist; 5, frying the twist; 6, packaging a finished product. The L-arabinose and tagatose are added into raw materials, people are prevented from absorbing saccharose and glucose, postprandial blood sugar increase is restrained, fat intake is reduced, the problem that diabetic population and the crowd avoiding sugar cannot eat twists are solved, and the sugar-controlled fried dough twist can be used for improving high glucose, high oil and high fat of traditional pastries.

The invention relates to a method and application of extracting naringenin from the Chinese traditional medicine, bamboo brier. The method includes pulverizing the Chinese traditional medicine bamboo brier, cold soaking in 70% ethanol to obtain the leach solution, concentrating to obtain the extract, suspending in distilled water, extracting and defatting with the petroleum ether, and extracting the defatted water phase with ethyl acetate; performing chromatography on the ethyl acetate phase in a silica gel column, eluting with ethyl acetate-methanol system (9:1), collecting the eluent part by part, combining and concentrating the frontmost segment, gradient eluting with chloroform: methanol with the silica gel column, collecting in a sectional manner, and concentrating to separate the precipitate; and repeatedly purifying with column, and re-crystallizing with methanol to obtain white needle crystal. In the method, pure 3(S)-5,7, 4'-trihydroxy flavanone, i.e., naringenin, extracted from the Chinese traditional medicine bamboo brier, has aldose reductase and Alpha-glucosidase inhibiting activity and is effective in adjusting and controlling glucose absorption of small intestine and preventing and treating diabetic complication. The purified monomer has clear structure and remarkable effect, which facilitates the quality control and the Chinese traditional medicine modernization process; and the naringenin can be further chemically modified to deeply study occurrence and development mechanism of diabetes and complication thereof so as to develop the new drug for treating diabetes and complication thereof.

The invention provides a sugar control biscuit, which comprises 30-60wt% flour, 8-12wt% fat, 6-9wt% sugar and 5-10wt% sugar control agent relative to the total weight of the biscuit. In the present invention, the starch absorption blocker, L-arabinose and tagatose are compounded, and the starch absorption blocker can block the absorption of starch, slow down the rise of blood sugar, and inhibit excess starch absorption in case of overeating. L‑arabinose and tagatose are low in calories, can block the absorption of sucrose and glucose, lower postprandial blood sugar, make blood sugar stable, and delay or reduce the occurrence and development of diabetic complications.

The invention relates to low-fat Chinese toon and melon seed kernel sausage slices. The sausage slices are made from the following raw materials in parts by weight: 15-25 parts of melon seed kernels,25-35 parts of Chinese toon buds, 70-80 parts of lean pork, 20-30 parts of fat pork, 3-5 parts of konjaku flour, 1-2 parts of carrageenin, 0.5-1.5 parts of potato starch, 1-2 parts of phosphate, 2-4 parts of edible salt, 0.5-1.5 parts of pricklyash peel powder, 0.5-1.5 parts of chili powder, 2-6 parts of Baijiu, 4-6 parts of white granulated sugar, 0.5-1.5 parts of monosodium glutamate and 0.5-1.5parts of a light soy sauce. The low-fat Chinese toon and melon seed kernel sausage slices made by the making method disclosed by the invention have the characteristics of being low in fat, low in cholesterol, low in salt content and high in protein, conform to the healthy diet idea of modern people, and can be eaten by old people, adults and children. According to the low-fat Chinese toon and melon seed kernel sausage slices disclosed by the invention, the raw materials are reasonably blended, and a microwave vacuum freeze drying technique is used for making the sausage slices, so that underthe premise that the original nutrient value of sausages is balanced, and the original nutrient does not run off, trace elements indispensable to human bodies are effectively complemented, glucose absorption and fat absorption are delayed, the blood fat level of blood sugar is gradually reduced, and healthy diet is achieved.

The present invention relates to food products comprising in percent by weight of dry matter, 0.5 - 5% of a viscous soluble fibre, 2 - 20% oat bran concentrate, and 7 - 35% cereal bran. The specific amount of these constituents provide for a high viscosity and are suitable to delay glucose absorption or appearance in blood and / or to maintain raised glucose levels while avoiding high glucose peaks. The high viscosity of a food product was shown to be a key factor in the appearance of glucose in the blood stream. Hence, the food products according to the present invention are also suitable for diabetic patients. <IMAGE>

This invention relates to a micromolecular organic compound that is used for activator of human embran mononucleotide activator protein kinase (AMPK). This compound can be used to prevent, postpone or cure diseases that are mediated by AMPK, especial type II diabetes, obesity and tumor. This invention also relates to the preparation of this compound. Otherwise, this invention also relates to application of this compound for activating human embran mononucleotide activator protein kinase or promoting intracellular amylaceum absorbing and application for preparing medicine that cure metabolic disease.

The invention relates to the technical field of a dairy product, particularly to brain-invigorating intelligence-improving yogurt powder. Yogurt powder comprises the following components, by mass part, 90-100 parts of milk powder, 10-20 parts of lactalbumin powder, 1-10 parts of lecithin, 10-20 parts of glucose, 0.1-2 parts of lactobacillus powder, 3-8 parts of soluble dietary fiber, 1-10 parts of red dates, 0.1-3 parts of dry spirulina powder, 0.001-0.005 part of vitamin B1, 0.001-0.005 part of allithiamine, calcium carbonate, zinc oxide, vitamin A, vitamin D, magnesium sulfate and vitamin E. The brain-invigorating intelligence-improving yogurt powder contains red dates, spirulina and vitamins, which can improve spirulina, increase blood supply to the brain, and maintain delivery of energy required for brain operation, contains glucose, allithiamine and vitamin B1, which can promote glucose absorption of the intestinal tracts and ensure energy supply to the brain, and contains lecithin, which can fight brain fatigue, repair damage of brain cells, and improves memory. The yogurt powder can be fermented by a customer himself or herself, the manufacture process is simple, and the yogurt powder is sour and sweet and delicious, and is suitable for people of all ages.

The invention discloses a sugar control lactic acid bacteria beverage- the lactic acid bacteria beverage can inhibit the absorption of cane sugar and glucose. The ingredients comprise, by mass, fresh milk 25%-90%, fungus powder 0.2%-3%, hydrolyzed animal protein 0.3%-5%, Arabia sugar 0.1%-30%, tagatose 0.1%-30%, cane sugar 5%-50%, potassium sorbate 0.01%-0.2%, stabilizer (HBT-00504)0.3%-5% and water 1%-15%, the preparing method comprise the steps of : 1. disinfection; 2. sterilization; 3. fermentation. 4. mixing; 5. bottling and 6. packaging. By adding L- Arabia sugar and tagatose, the beverage can prevent the human body from absorbing cane sugar and glucose, inhibit the increasing of sugar blood and reduce the fat intake; the beverage solves the problem of consuming lactic acid bacteria beverage for people with diabetes and people who can not eat sugar.